BioNTech And Duality Biologics Announced FDA Granted Fast Track Designation For BNT324/DB-1311 For Advanced/Unresectable, Or Metastatic Castration-resistant Prostate Cancer Patients Who Have Progressed On Or After Standard Systemic Regimens
BioNTech And Duality Biologics Announced FDA Granted Fast Track Designation For BNT324/DB-1311 For Advanced/Unresectable, Or Metastatic Castration-resistant Prostate Cancer Patients Who Have Progressed On Or After Standard Systemic Regimens
BioNTech和Duality Biologics宣佈BNT324/DB-1311在標準系統方案後進展的晚期/無法手術或轉移的去勢抵抗性前列腺癌患者獲得FDA快速通道認定。
BioNTech And Duality Biologics Announced FDA Granted Fast Track Designation For BNT324/DB-1311 For Advanced/Unresectable, Or Metastatic Castration-resistant Prostate Cancer Patients Who Have Progressed On Or After Standard Systemic Regimens
BioNTech和Duality Biologics宣佈BNT324/DB-1311在標準系統方案後進展的晚期/無法手術或轉移的去勢抵抗性前列腺癌患者獲得FDA快速通道認定。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。